FDA again finds Amylyx's ALS data lacking ahead of unusual second adcomm, while stressing dire need for treatments
The FDA’s briefing docs are in ahead of its unusual second adcomm for Amylyx Pharmaceuticals’ experimental ALS drug next week — and the agency’s opinion is largely negative.
While acknowledging that ALS treatments are “desperately needed” and providing an extensive history of their previous flexibility for the disease, FDA reviewers wrote that Amylyx’s submission of new analyses is “not independent data and is simply a new method for analyzing the same survival data presented in the original NDA submission.” The new data packages involve patients who switched over from treatment to placebo after the Phase II trial wrapped up, suggesting better survival results than the study originally indicated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.